Like most websites, we use cookies and other similar technologies for a number of reasons, such as keeping our website reliable and secure, personalizing content, providing social media features and to better understand how our site is used. By using our site, you are agreeing to our use of these tools. Learn More

Your Location is set to:

ADEPT

A single arm phase II study of ADjuvant Endocrine therapy, subcutaneous Pertuzumab, and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor positive, HER2-positive breast cancer -- NCT04569747

Objective

 This clinical trial aims to evaluate invasive disease-free survival when treated with a "de-escalated" regimen of hormonal and dual HER2-targeted therapy, with omission of chemotherapy. Objective is to evaluate 3-year invasive disease-free survival in patients with stage I HR+ HER2+ breast cancer treated with adjuvant HP plus endocrine therapy.

Principal Investigator(s)
Edward Wyluda, DO

Clinical Trial Categories

  • Treatment
  • Breast Cancer
Contact
Christine Neely-Jones, RN at 508-862-7298
or cneelyjones@capecodhealth.org
How to Participate

Contact your oncologist, oncology nurse or the Oncology Research Program Manager.